CYTOKINETICS INC

(c) In this Item 5(c) of this quarterly report on Form 10-Q, the terms “officers”, “rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” have the meanings ascribed to them in Item 408 of Regulation S-K.

The following directors and officers adopted into or terminated a Rule 10b5-1 trading arrangement during the first quarter of 2026:

•

Edward M. Kaye, M.D. – Dr. Kaye, a member of our board of directors, adopted a Rule 10b5-1 trading arrangement on March 2, 2026 that was intended to satisfy the affirmative defense provided for under Rule 10b5-1(c) (the “Kaye Plan”). The Kaye Plan provides for the sale of up to 29,347 shares of our common stock, subject to certain conditions. The Kaye Plan will terminate on theearlier of (x)February 28, 2027 and (y) the sale of all securities that are subject to the plan.

Certain of our officers have made elections to participate in, and are participating in, our employee stock purchase plan, which may be designed to satisfy the affirmative defense conditions of Rule 10b5-1 under the Exchange Act or may constitute non-Rule 10b5–1 trading arrangements. In addition, certain of our directors have made elections to participate in, and are participating in, our director equity in lieu of cash retainer option program (as described in the “Director Compensation” section of our Proxy Statement for our 2024 Annual Meeting), which may be designed to satisfy the affirmative defense conditions of Rule 10b5-1 under the Exchange Act or may constitute non-Rule 10b5–1 trading arrangements.